Eletriptan Orion

What Is Eletriptan Orion and What Is It Used For?

Eletriptan Orion is a selective serotonin (5-HT1B/1D) receptor agonist, commonly known as a triptan, prescribed for the acute treatment of migraine headaches with or without aura in adults. It relieves migraine pain by narrowing dilated cranial blood vessels and blocking the release of pro-inflammatory neuropeptides.

Migraine is a complex neurological condition that affects approximately 12% of the global population, with women being affected roughly three times more often than men. A migraine attack typically involves moderate to severe throbbing headache, often on one side of the head, accompanied by nausea, vomiting, and heightened sensitivity to light (photophobia) and sound (phonophobia). Attacks can last from 4 to 72 hours if untreated.

Eletriptan belongs to the triptan family of drugs, which were specifically developed to target the pathophysiology of migraine. Unlike simple analgesics (such as paracetamol or ibuprofen) that provide non-specific pain relief, triptans work by binding to serotonin 5-HT1B receptors on cranial blood vessels, causing vasoconstriction, and to 5-HT1D receptors on trigeminal nerve endings, inhibiting the release of vasoactive neuropeptides including calcitonin gene-related peptide (CGRP) and substance P.

Eletriptan is considered one of the more potent triptans, with clinical trials demonstrating headache relief rates of 54-65% at 2 hours after a 40 mg dose, compared to 22-30% with placebo. The 20 mg dose available in Eletriptan Orion provides an effective starting dose, particularly suitable for patients who may be more sensitive to triptan effects or who are trying a triptan for the first time.

It is important to understand that Eletriptan Orion is an acute treatment medicine — it should be taken when a migraine headache is already present. It is not intended for the prevention of migraine attacks, nor should it be taken during the aura phase before headache onset. Taking it during the aura phase has not been shown to prevent the subsequent headache from developing.

What Should You Know Before Taking Eletriptan Orion?

Before taking Eletriptan Orion, your doctor must rule out cardiovascular disease, uncontrolled hypertension, severe liver impairment, and recent use of other triptans or ergotamine. A cardiovascular evaluation is recommended for patients with risk factors such as smoking, obesity, diabetes, or family history of heart disease.

Eletriptan Orion, like all triptans, causes vasoconstriction (narrowing of blood vessels). While this action is primarily targeted at cranial blood vessels, there is a potential for coronary artery vasoconstriction. For this reason, thorough medical evaluation is essential before starting treatment, particularly in patients who may have unrecognised cardiovascular disease.

Contraindications

Eletriptan Orion must not be used in the following situations:

• Hypersensitivity to eletriptan hydrobromide or any of the excipients in the tablet
• Ischaemic heart disease including angina pectoris, history of myocardial infarction, or documented silent ischaemia
• Coronary artery vasospasm including Prinzmetal's angina
• Uncontrolled hypertension or moderately severe to severe hypertension, even if treated
• Severe hepatic impairment (Child-Pugh grade C)
• Peripheral vascular disease including signs or symptoms consistent with ischaemic bowel disease
• History of cerebrovascular accident (stroke) or transient ischaemic attack (TIA)
• Concurrent use of another triptan or ergotamine-containing medicine within 24 hours
• Concurrent use of potent CYP3A4 inhibitors such as ketoconazole, itraconazole, nefazodone, clarithromycin, ritonavir, or nelfinavir

Warnings and Precautions

Eletriptan Orion should be used with caution in several clinical situations. Patients with cardiovascular risk factors — including hypertension, hypercholesterolaemia, smoking, obesity, diabetes, strong family history of coronary artery disease, men over 40 years, and postmenopausal women — should undergo cardiovascular evaluation before receiving their first dose. Ideally, the first dose should be administered in a medically supervised setting.

Triptan sensations, such as chest tightness, pressure, or heaviness, can occur after taking eletriptan. These symptoms are usually benign and not of cardiac origin, but they should be evaluated if they are severe or persistent. Patients should be instructed to seek immediate medical attention if they experience chest pain, shortness of breath, or symptoms suggestive of angina.

Medication-overuse headache (MOH) is a significant concern with all acute migraine treatments, including triptans. Regular use of eletriptan on 10 or more days per month for 3 months or longer can lead to chronic daily headache that worsens with continued use. If medication-overuse headache is suspected, eletriptan should be discontinued under medical supervision.

Serotonin syndrome is a rare but potentially life-threatening condition that can occur when triptans are used concurrently with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or other serotonergic drugs. Symptoms include agitation, hallucinations, rapid heartbeat, fever, muscle rigidity, and incoordination. If serotonin syndrome is suspected, eletriptan and all serotonergic agents should be discontinued immediately.

Pregnancy and Breastfeeding

There is limited clinical data on the use of eletriptan during pregnancy. Animal studies have shown reproductive toxicity at doses significantly higher than the maximum recommended human dose. Eletriptan Orion should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the foetus. Women of childbearing potential should use effective contraception during treatment.

Eletriptan is excreted in human breast milk. In a study of eight breastfeeding women, the mean total amount of eletriptan in breast milk over 24 hours was approximately 0.02% of the administered dose. To minimise infant exposure, breastfeeding should be avoided for 24 hours after taking Eletriptan Orion. Breast milk expressed during this period should be discarded.

How Does Eletriptan Orion Interact with Other Drugs?

Eletriptan is primarily metabolised by the CYP3A4 enzyme. Potent CYP3A4 inhibitors are contraindicated as they can increase eletriptan plasma levels by up to 6-fold. Other triptans and ergotamine must not be used within 24 hours. Caution is required with SSRIs, SNRIs, and other serotonergic agents due to the risk of serotonin syndrome.

Drug interactions with eletriptan can be pharmacokinetic (affecting how the body processes the drug) or pharmacodynamic (affecting how the drug works). The most clinically significant interactions involve the CYP3A4 enzyme system, which is the primary pathway for eletriptan metabolism. When CYP3A4 activity is inhibited, eletriptan plasma concentrations increase dramatically, raising the risk of adverse effects including coronary artery vasospasm.

In a pharmacokinetic study, co-administration of eletriptan with ketoconazole (a potent CYP3A4 inhibitor) increased the eletriptan AUC (area under the curve, a measure of total drug exposure) by approximately 6-fold and the maximum plasma concentration (Cmax) by approximately 2-fold. This significant increase in drug exposure makes the combination contraindicated.

Major Interactions

Minor Interactions and Precautions

What Is the Correct Dosage of Eletriptan Orion?

The recommended starting dose of Eletriptan Orion is 20 mg taken orally at the onset of migraine headache. If the headache recurs after initial relief, a second dose may be taken after at least 2 hours. The maximum daily dose is 40 mg. Do not take a second dose if the first dose provided no relief.

Eletriptan Orion should be taken as early as possible after the onset of migraine headache, although it is effective at any time during the attack. The tablet should be swallowed whole with water. It can be taken with or without food, although food may slightly delay absorption. Clinical efficacy is not significantly affected by food intake.

Adults (18-65 years)

The efficacy of eletriptan has been demonstrated in multiple randomised, double-blind, placebo-controlled trials. At the 20 mg dose, approximately 47-54% of patients achieve headache relief (reduction from moderate or severe pain to mild or no pain) at 2 hours, compared to 22-30% with placebo. For patients who respond to the first dose but experience headache recurrence, a second dose is usually effective.

Children and Adolescents (under 18 years)

Elderly Patients (over 65 years)

Special Populations

Missed Dose

Eletriptan Orion is taken on an as-needed basis for acute migraine attacks, so the concept of a missed dose does not apply in the traditional sense. If you forget to take it at the onset of a migraine, you can still take it at any point during the headache phase. The medicine is effective even if taken later in the attack, although earlier treatment generally leads to faster relief.

Overdose

In clinical studies, volunteers who received single oral doses of up to 120 mg of eletriptan did not experience significant adverse effects beyond those seen at therapeutic doses, although the incidence and severity of expected side effects (dizziness, drowsiness, nausea, chest tightness) increased. There is no specific antidote for eletriptan overdose.

In the event of overdose, standard supportive measures should be employed. These include monitoring for cardiovascular effects (blood pressure, heart rate, ECG) for at least 20 hours, given that the elimination half-life of eletriptan is approximately 4 hours. Gastric lavage may be considered if performed within 1 hour of ingestion. The effects of haemodialysis or peritoneal dialysis on eletriptan clearance are unknown.

What Are the Side Effects of Eletriptan Orion?

The most common side effects of Eletriptan Orion include dizziness, drowsiness, headache (non-migraine), nausea, dry mouth, and sensations of tingling, pressure, or tightness. Most side effects are mild to moderate and resolve spontaneously. Seek immediate medical attention for chest pain, signs of allergic reaction, or symptoms of serotonin syndrome.

Like all medicines, Eletriptan Orion can cause side effects, although not everybody experiences them. The frequency and severity of side effects generally increase with higher doses. Most adverse effects are transient and resolve within a few hours without specific treatment. In clinical trials involving over 5,000 patients, eletriptan was generally well tolerated with a safety profile consistent with other triptans.

The following side effects have been reported in clinical trials and post-marketing surveillance. They are organised by frequency according to the standard medical classification:

If you experience any side effects not listed above, or if any of the listed side effects become severe or bothersome, contact your healthcare provider. You can also report side effects to your national pharmacovigilance authority to help monitor medicine safety.

How Should You Store Eletriptan Orion?

Store Eletriptan Orion at room temperature below 30°C in the original packaging to protect from moisture and light. Keep out of reach and sight of children. Do not use after the expiry date printed on the packaging.

Proper storage of Eletriptan Orion is important to maintain its effectiveness and safety. The film-coated tablets should be stored in their original blister packaging until the time of use. Exposure to excessive heat, humidity, or light can degrade the active ingredient and reduce the medicine's efficacy.

Key storage guidelines include:

• Temperature: Store below 30°C (86°F). Do not refrigerate or freeze.
• Light: Keep in the original packaging to protect from light.
• Moisture: Store in a dry place. Do not remove tablets from the blister pack until ready to take them.
• Children: Keep out of the reach and sight of children.
• Expiry: Do not use the tablets after the expiry date stated on the carton and blister. The expiry date refers to the last day of that month.

Do not dispose of medicines via household waste or wastewater. Return unused or expired medicines to a pharmacy for safe disposal. This helps protect the environment and prevents accidental ingestion.

What Does Eletriptan Orion Contain?

Each Eletriptan Orion 20 mg film-coated tablet contains eletriptan hydrobromide equivalent to 20 mg of eletriptan as the active substance, along with several inactive ingredients (excipients) necessary for tablet formulation, coating, and stability.

The active ingredient in Eletriptan Orion is eletriptan hydrobromide. It is a second-generation triptan with the chemical name (R)-3-[(1-methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole monohydrobromide. Eletriptan hydrobromide is a white to off-white crystalline powder that is soluble in water.

The inactive ingredients (excipients) in the tablet core typically include:

• Microcrystalline cellulose (bulking agent)
• Lactose monohydrate (filler)
• Croscarmellose sodium (disintegrant)
• Magnesium stearate (lubricant)

The film coating typically contains:

• Hypromellose (film-forming agent)
• Titanium dioxide (E171, colourant)
• Lactose monohydrate
• Triacetin (plasticiser)

Patients with known lactose intolerance should be aware that the tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. If you are allergic to any of the listed excipients, inform your healthcare provider before starting treatment.